Jacobio Pharma Announces 2022 Annual Results
BEIJING, SHANGHAI and BOSTON, March 22, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced its 2022 annual results. R&D investment wasRMB530 million, showing an increase of 26% compared with 2021. The revenue wasRMB95.7 million, which was generated from an out-licensing deal. Jacobio Pharma ...
Jacobio announces clinical collaboration to evaluate CD73 monoclonal antibody JAB-BX102 in combination with KEYTRUDA® (pembrolizumab) for patients with cancer
BEIJING, SHANGHAI and BOSTON, March 22, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has entered into a clinical collaboration with Merck & Co., Inc.,Rahway, NJ, USA to evaluate the combination of Jacobio's CD73 monoclonal antibody JAB-BX102 in combination with Merck & Co., Inc., Ra...
Jacobio Pharma to Present Data of Three Preclinical Studies at the 2023 AACR Annual Meeting
BEIJING and SHANGHAI and BOSTON, Mass., March 14, 2023 /PRNewswire/ -- Jacobin Pharma (1167.HK) today announced that the company will present the results of three preclinical studies of KRASmulti inhibitor JAB-23425, CD73-STING iADC JAB-X1800, and Aurora kinase A inhibitor JAB-2485 in form of the...
Jacobio Completes First Patient Dosage of Aurora A Inhibitor JAB-2485 in U.S
BEIJING and SHANGHAI and BOSTON, Jan. 8, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has completedthe first patient dosage of its in-house R&D drug candidate Aurora A Inhibitor JAB-2485 in a Phase I/IIa clinical trial for advanced solid tumour patients in U.S. JAB-2485 is a high...
Jacobio's KRAS G12C Inhibitor JAB-21822 was Granted Breakthrough Therapy Designations by China CDE
BEIJING, SHANGHAI and BOSTON, Dec. 15, 2022 /PRNewswire/ -- Jacobio Pharma (1167. HK) announced that the Company's in-house KRAS G12C inhibitor JAB-21822 was granted breakthrough therapy designations for the second line and above treatment of advanced or metastatic non-small cell lung cancer (NSC...
Jacobio's Preclinical Results of KRAS G12C Inhibitor in Combination with SHP2 Inhibitor Will be Presented at the ESMO Asia Congress 2022
BEIJING, SHANGHAI and BOSTON, Dec. 1, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) will present the results of KRAS G12C inhibitor JAB-21822 as a single agent or in combination withSHP2 inhibitor JAB-3312 in preclinical cancer models in a poster session during the 2022 European Society of Medica...
Jacobio Pharma to Collaborate with Merck on Clinical Trial of JAB-21822 in Combination with Cetuximab
BEIJING, SHANGHAI and BOSTON, Oct. 13, 2022 /PRNewswire/ -- Jacobio announced it has entered into a clinical trial collaboration agreement with Merck on clinical study of combination therapy between Jacobio's KRAS G12C inhibitor JAB-21822 and Merck's epidermal growth factor receptor (EGFR) inhibi...
Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-218822's Phase II Pivotal Study in China
BEIJING, SHANGHAI and BOSTON, Sept. 6, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) has received Phase II pivotal study approval of KRAS G12C inhibitor JAB-21822 from the Center for Drug Evaluation (CDE) ofChina in September 5, 2022 . This study aims to treat advanced or metastatic non-small cell...
Jacobio Completes First Patient Dosage of CD73 mAb JAB-BX102 in China
BEIJING, Sept. 2, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has completed first patient dosage of it's in-house R&D drug candidate CD73 monoclonal antibody JAB-BX102 in a Phase I/IIa clinical trial for advanced solid tumour patients. This is a phase I/IIa multi-center, open-la...
Jacobio Completes First Dose of IIa Clinical Trial of JAB-21822 on KRAS G12C and STK11 Co-mutation in China
BEIJING, Sept. 1, 2022 /PRNewswire/ -- JacobioPharma (1167.HK) announced that the company has dosed the first non-small cell lung cancer (NSCLC) patient with KRAS G12C and STK11 co-mutation in the Phase IIa trial of KRAS G12C inhibitor JAB-21822 inChina. JAB-21822 is a KRAS G12C inhibitor inde...
Jacobio Pharma Announces 2022 Interim Results
Investment in R&D increased 26.3% to RMB 221 million. Recorded revenue was RMB 54.7 million. Global development of KRAS G12C inhibitor and other clinical stage drug candidates accelerated. Development started in new pre-clinical stage drug candidates, such as iADC (immunostimulatory antibody-dr...
Jacobio will Present Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822 at the 2022 ASCO Annual Meeting
BEIJING, SHANGHAI and BOSTON, May 27, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) is pleased to announce that the phase I clinical data of KRAS G12C inhibitor JAB-21822 will be presented in the form of poster at the upcoming 2022 annual meeting of American Society of Clinical Oncology (ASCO) fr...
Jacobio Announces Annual Results of 2021, R&D Investment Increases 83%
BEIJING and SHANGHAI and BOSTON, March 22, 2022 /PRNewswire/ -- Jacobio Announced its 2021 annual results on 22 March. As a clinical-stage biotech company, Jacobio's revenue wasRMB152 million, which was generated from an out-licensing deal. Its R&D investment wasRMB421 million, showing an increas...
Jacobio JAB-21822 in Combination with Cetuximab Completes First Dose of Colorectal Cancer Patient in China
BEIJING, SHANGHAI and BOSTON, Feb. 23, 2022 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) announced that its KRAS G12C inhibitor JAB-21822 completed the first patient dosing in combinationtherapy with Cetuximab at Peking University Cancer Hospital recently. JAB-21822 in combination with ce...
Jacobio Receives IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China
BEIJING and SHANGHAI and BOSTON, Dec. 5, 2021 /PRNewswire/ -- Jacobio Pharma ( 1167.HK) has received the Investigational New Drug (the "IND") approval of the combination therapy of KRAS G12C inhibitor JAB-21822 and Cetuximab injection from the Center for Drug Evaluation ofChina (the "CDE") on Dec...
Jacobio Announces Strategic Investment in Hebecell to Further Develop iPSC-NK Cell Therapy
BEIJING and SHANGHAI and BOSTON, Aug. 31, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals ("Jacobio", 1167.HK) announced a strategic investment in the US-based biotech company Hebecell onAugust 31. Jacobio will collaborate with Hebecell to develop thenext-generation natural killer cell therapy based...
Jacobio Pharmaceuticals Announces 2021 Interim Results
BEIJING and SHANGHAI and BOSTON, Aug. 31, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals ("Jacobio", 1167.HK) announced its results for the first half of 2021. Investment in R&D for the clinical-stage biotech firm reached175 million yuan (approx. US$27 million) for the half year, up 146 percent ye...
Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor
BEIJING, Aug. 3, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) today announced the first patient was dosed in a Phase I/II clinical trial of KRAS G12C inhibitor JAB-21822 inChina. JAB-21822 is Jacobio's innovative in-house small molecule anti-cancer drug, which is designed to target t...
Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering US$20 Million Milestone Payment
BEIJING and SHANGHAI and BOSTON, June 18, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) has announced that the first two patients have been dosed in the Phase 1/2a clinical trial ofSHP2 inhibitor JAB-3312 in combination with PD-1 antibody Pembrolizumab and MEK inhibitor Binimetinib respe...
Jacobio Announces FDA Approves IND Application to Develop KRAS G12C Inhibitor
BEIJING and SHANGHAI and BOSTON, May 2, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) has announced the U.S. Food and Drug Administration (FDA) has approved company's Investigational New Drug (IND) application to develop a KRAS G12C inhibitor. IND application to the National Medical Pro...
